Elucidating the roles of alveolar macrophage inflammation and self renewal during influenza infection

  • Funded by National Institutes of Health (NIH)
  • Total publications:0 publications

Grant number: 2R01AG069264-07

Grant search

Key facts

  • Disease

    Unspecified
  • Start & end year

    2020
    2030
  • Known Financial Commitments (USD)

    $614,905
  • Funder

    National Institutes of Health (NIH)
  • Principal Investigator

    PROFESSOR Jie Sun
  • Research Location

    United States of America
  • Lead Research Institution

    UNIVERSITY OF VIRGINIA
  • Research Priority Alignment

    N/A
  • Research Category

    Pathogen: natural history, transmission and diagnostics

  • Research Subcategory

    Immunity

  • Special Interest Tags

    N/A

  • Study Type

    Non-Clinical

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Not Applicable

  • Vulnerable Population

    Not applicable

  • Occupations of Interest

    Not applicable

Abstract

Summary Respiratory viral infections, such as influenza and SARS-CoV-2, pose significant public health challenges, particularly affecting older adults with severe outcomes and long-term health issues like Post-Acute Sequelae of SARS-CoV-2 (PASC). Alveolar macrophages (AMs), the primary macrophage population in the lungs, play crucial roles in lung defense and tissue repair, but can become pro-inflammatory during infections, leading to tissue damage. Our previous studies identified that TCF4 and β-catenin, key transcription factors in WNT signaling, have opposing effects on AM responses: TCF4 supports AM stem- like self-renewal, while β-catenin enhances inflammatory responses. Additionally, AMs from aged mice and humans exhibit "senescence-like" characteristics, likely contributing to adverse outcomes in the respiratory tract during aging. The aims of this grant are to elucidate the reciprocal regulation of TCF4 and β-catenin in dictating AM fate and function, and to investigate the roles of AM senescence, controlled by TCF4, in lung health and virus-associated acute and chronic diseases during aging. Furthermore, we aim to develop therapeutic strategies targeting TCF4 to treat age-related acute and chronic conditions following respiratory viral infections. The successful completion of this application will shed light on the molecular basis underlying the age-associated defects in host response to viral infection and could open the door for novel therapeutics for severe acute diseases and/or chronic lung sequelae after viral infection in aged individuals.